Integra LifeSciences Holdings Corporation (IART)
| Market Cap | 5.59B |
| Revenue (ttm) | 1.37B |
| Net Income (ttm) | 133.89M |
| Shares Out | 84.65M |
| EPS (ttm) | 1.57 |
| PE Ratio | 42.17 |
| Forward PE | 23.58 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $66.20 |
| Previous Close | $65.91 |
| Change ($) | 0.29 |
| Change (%) | 0.44% |
| Day's Open | 66.69 |
| Day's Range | 64.95 - 66.83 |
| Day's Volume | 518,674 |
| 52-Week Range | 34.21 - 71.34 |
After the rise of 10-year yields terrified investors, the indices “reverse rotated” back into the Nasdaq and out of the Dow. Make the most of this market with today's top buys, from Q.ai's Art...
Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically.
Integra (IART) fourth-quarter 2020 revenues fell 1.6% year over year to $388.6 million but rose 5% sequentially.
PRINCETON, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it is participati...
Integra (IART) delivered earnings and revenue surprises of 13.51% and 0.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Integra Lifesciences (NASDAQ:IART) moved higher by 0.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 23.53% year over y...
Integra Lifesciences Holdings Corp (NASDAQ: IART) reported Q4 adjusted EPS $0.84 better than the consensus estimate of $0.73 and revenues of $388.6 million in line with expectations. Revenues ...
PRINCETON, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full-year ended December...
The acquisition is expected to remain accretive to Integra's (IART) revenue growth and adjusted gross margins.
PRINCETON, N.J., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it completed the previo...
Integra's (IART) sales improvement in the fourth quarter is likely to have been boosted by on-going business recovery.
PRINCETON, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited prel...
Integra (IART) does not expect the selloff to have a material impact on its 2020 results.
PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has completed its pr...
Integra (IART) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.
Integra (IART) expects to close the ACell acquisition in the first quarter of 2021, subject to fulfilment of closing conditions.
PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Peter Arduini, pr...
Integra LifeSciences is in the late stages of a transition period, rounded off by the recent divestiture of the orthopaedics segment, to be closed next year. The company has had a strong seque...
Let's see if Integra LifeSciences (IART) stock is a good choice for value-oriented investors right now from multiple angles.
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Integra's (IART) third-quarter 2020 results reflect mixed segmental performance with strong recovery trends due to coronavirus-led business disruptions.
Integra LifeSciences Holdings Corporation (IART) CEO Peter Arduini on Q3 2020 Results - Earnings Call Transcript
Integra (IART) delivered earnings and revenue surprises of 40.35% and 0.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Integra Lifesciences (NASDAQ:IART) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 17.65% year over year to $0.80, which beat ...
PRINCETON, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for t...
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra's (IART) sales improvement in the third quarter is broad-based across the major franchises as per preliminary statement.
PRINCETON, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited prel...
Smith & Nephew SNN, +2.16% SN, -0.91% said it's buying the extremity orthopedics unit of Integra LifeSciences IART, ...
PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has entered into ...
Integra (IART) reported earnings 30 days ago. What's next for the stock?
PRINCETON, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it will part...
Integra's (IART) second-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.
Integra LifeSciences Holdings (IART) Q2 2020 Results - Earnings Call Transcript
Integra (IART) delivered earnings and revenue surprises of 312.50% and 1.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
PRINCETON, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for...
On Monday, August 10, Integra Lifesciences (NASDAQ: IART) will release its latest earnings report.
Integra LifeSciences (IART) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
First and Only Ultrasonic Tissue Ablation System Cleared to Treat Malignant and Benign Tumors, but Not Limited to Meningiomas and Gliomas First and Only Ultrasonic Tissue Ablation System Clear...
Integra (IART) projects a severe impact on revenues due to the coronavirus-led economic crisis despite sequential improvement in monthly sales performance throughout the quarter.
PRINCETON, N.J., July 09, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited pr...
Integra (IART) reported earnings 30 days ago. What's next for the stock?
PRINCETON, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced changes to its executive leadership team. Michael McBreen, who is ...
Data Shows IBWM Reduced Operating Room Time and Costs Associated with Lower Extremity Wounds Data Shows IBWM Reduced Operating Room Time and Costs Associated with Lower Extremity Wounds
Integra Lifesciences Holdings Corp (IART) CEO Peter Arduini on Q1 2020 Results - Earnings Call Transcript
Integra's (IART) first-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.
Integra (IART) delivered earnings and revenue surprises of -20.00% and 0.46%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About IART
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial... [Read more...]
| Industry Medical Devices | IPO Date Aug 16, 1995 |
| CEO Peter Arduini | Employees 3,700 |
| Stock Exchange NASDAQ | Ticker Symbol IART |
Financial Performance
In 2020, IART's revenue was $1.37 billion, a decrease of -9.60% compared to the previous year's $1.52 billion. Earnings were $133.89 million, an increase of 166.71%.
Analyst Forecasts
According to 14 analysts, the average rating for IART stock is "Buy." The 12-month stock price forecast is 70.33, which is an increase of 6.24% from the latest price.